New options for second-line therapy of advanced renal cancer
Mené sur 723 patients atteints d'un carcinome rénal à cellules claires de stade métastatique, cet essai de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité de l'axitinib et du sorafenib en traitement de deuxième ligne
Several drugs targeting VEGF or mTOR pathways have been approved for treatment of advanced renal-cell carcinoma because of improvements noted in progression-free survival (PFS) in phase 3 trials. Validation of prognostic models showed that treatment with such drugs can lead to a median overall survival of around 43 months for patients in favourable risk categories and 23 months for patients in intermediate risk categories. With few exceptions, patients on first-line therapy progress and proceed ...